PRA Health Sciences Expands Global Phase I Patient Strategy
31 March 2015 - 1:00AM
PRA Health Sciences (PRA) is enhancing its global Phase I patient
strategy and increasing its clinical footprint with the expansion
of its Early Development Services (EDS). These initiatives are
being undertaken in response to market demand to include patients
as early as possible in early phase clinical trial development and
include:
- Opening an 11,000 square foot outpatient facility at PRA's Salt
Lake City, Utah site, focusing on psychiatry, neurology, pain and
multiple other therapeutic areas. The new facility includes a
dedicated pharmacy, clinical lab and surgical suites.
- Further enhancing PRA's U.S. patient capabilities and service
offerings by implementing proven operational site models in our
Marlton, New Jersey facility similar to those utilized in our
Patient Pharmacology Services operations in Central and Eastern
Europe.
- Expanding PRA's Patient Pharmacology Services into Russia. The
first clinical trial application was recently submitted for a
rheumatoid arthritis patient study and approval is expected in
April.
- Expanding PRA's Human Abuse Liability (HAL) study capabilities
at its Lenexa, Kansas site. This positions PRA as the only contract
research organization (CRO) capable of conducting these specialized
trials in more than one clinical pharmacology unit.
"With PRA conducting more than half of its Phase I/IIa studies
in patients vs. volunteers, these initiatives will further enhance
our U.S. patient capabilities and service offerings," said Randall
Hein, Senior Vice President, Clinical Research Services.
Arnoud Huisman, MSc, Senior Vice President Global Business
Development, EDS added, "This increased capacity will allow PRA to
meet the increased high demand for patient studies, HAL studies,
pain and other indications."
PRA EDS is a business unit of PRA Health Sciences, offering full
service Phase I capabilities and Phase I-III patient site services.
Global capabilities include: eight clinical pharmacology units, two
bioanalytical laboratories, as well as dedicated clinical
pharmacology, statistics, data management and pharmacokinetics
services.
ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is one of the world's leading global
contract research organizations (CRO), providing outsourced
clinical development services to the biotechnology and
pharmaceutical industries. At PRA, providing innovative solutions
for our clients is what we do. Side-by-side with our clients, we
strive to move drug discovery forward, helping them to develop
life-saving and life-improving drugs. PRA has more than 11,000
employees working in 80+ countries providing comprehensive clinical
development services across all phases. From full service clinical
development to the pioneering Embedded Solutions™ model, PRA
provides a broad spectrum of solutions that meet the demands of a
diverse marketplace. PRA has worked on 100+ marketed drugs across
several therapeutic areas and conducted the pivotal or supportive
trials that led to FDA and/or international regulatory approval of
50+ such drugs.
CONTACT: MEDIA INQUIRIES:
Christine Rogers, Manager - Public Relations,
Corporate Communications
EMAIL: rogerschristine@prahs.com
PHONE: +1 919.786.8463
INVESTOR INQUIRIES:
InvestorRelations@prahs.com
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Mar 2024 to Apr 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Apr 2023 to Apr 2024